Physician profile
Debaroti M Addy
NPI 1023016235
$1,664.63
in general payments reported to CMS, 2019-2025
24 companies · $376 in 2025
The $376 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $107 · 2021: $179 · 2022: $178 · 2023: $342 · 2024: $354 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $332.21 | 2019-2025 | Bexsero |
| Cranial Technologies, INC | $245.09 | 2019-2025 | Doc Band |
| Corium, LLC | $200.40 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $144.25 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $120.72 | 2021-2025 | Gardasil 9, Enflonsia, M-M-R II |
| Tris Pharma INC | $84.57 | 2020-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $62.92 | 2025 | Jornay Pm |
| Pfizer INC. | $58.85 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $52.29 | 2024 | |
| Alk-Abello, INC | $50.89 | 2023-2025 | Neffy, Grastek, Odactra |
| Seqirus USA INC | $43.31 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Kaleo, INC. | $36.60 | 2020-2023 | Auvi-Q |
| Kowa Pharmaceuticals America, INC. | $31.72 | 2025 | Zoryve |
| Acadia Pharmaceuticals INC | $26.39 | 2023 | Daybue |
| Abbott Laboratories | $24.81 | 2025 | Id Now Instrument |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $21.27 | 2025 | Spinosad, Natroba |
| Ironwood Pharmaceuticals, INC | $18.22 | 2024 | |
| Arbor Pharmaceuticals, INC. | $18.13 | 2019 | |
| Avion Pharmaceuticals | $16.86 | 2023 | Methylphenidate Hydrochloride |
| Adlon Therapeutics L.P. | $16.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.01 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $15.68 | 2025 | Neffy |
| Dermira, INC. | $15.19 | 2019 | |
| Sobi, INC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debaroti Addy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.